FR19C1073I2 - Inhibition de l'absorption renale de molecules pouvant potentiellement endommager les reins a l'aide d'une combinaison de lysine et d'arginine - Google Patents

Inhibition de l'absorption renale de molecules pouvant potentiellement endommager les reins a l'aide d'une combinaison de lysine et d'arginine

Info

Publication number
FR19C1073I2
FR19C1073I2 FR19C1073C FR19C1073C FR19C1073I2 FR 19C1073 I2 FR19C1073 I2 FR 19C1073I2 FR 19C1073 C FR19C1073 C FR 19C1073C FR 19C1073 C FR19C1073 C FR 19C1073C FR 19C1073 I2 FR19C1073 I2 FR 19C1073I2
Authority
FR
France
Prior art keywords
arginine
lysine
kidney
inhibition
molecules
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR19C1073C
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Advanced Accelerator Applications USA Inc
Original Assignee
Advanced Accelerator Applications USA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Advanced Accelerator Applications USA Inc filed Critical Advanced Accelerator Applications USA Inc
Publication of FR19C1073I1 publication Critical patent/FR19C1073I1/fr
Application granted granted Critical
Publication of FR19C1073I2 publication Critical patent/FR19C1073I2/fr
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/083—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being octreotide or a somatostatin-receptor-binding peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
FR19C1073C 1999-07-16 2019-12-09 Inhibition de l'absorption renale de molecules pouvant potentiellement endommager les reins a l'aide d'une combinaison de lysine et d'arginine Active FR19C1073I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14410699P 1999-07-16 1999-07-16
PCT/EP2000/006917 WO2001005383A2 (fr) 1999-07-16 2000-07-17 Inhibition de l'absorption renale de molecules pouvant potentiellement endommager les reins

Publications (2)

Publication Number Publication Date
FR19C1073I1 FR19C1073I1 (fr) 2020-01-17
FR19C1073I2 true FR19C1073I2 (fr) 2020-12-18

Family

ID=22507065

Family Applications (1)

Application Number Title Priority Date Filing Date
FR19C1073C Active FR19C1073I2 (fr) 1999-07-16 2019-12-09 Inhibition de l'absorption renale de molecules pouvant potentiellement endommager les reins a l'aide d'une combinaison de lysine et d'arginine

Country Status (7)

Country Link
EP (1) EP1196154B1 (fr)
JP (1) JP2003504395A (fr)
AU (1) AU6275800A (fr)
CA (1) CA2379696C (fr)
DE (1) DE60030722T2 (fr)
FR (1) FR19C1073I2 (fr)
WO (1) WO2001005383A2 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002275059A (ja) * 2001-03-15 2002-09-25 Inst Of Physical & Chemical Res 腎機能障害改善用アミノ酸組成物
FI20010764A0 (fi) * 2001-04-11 2001-04-11 Map Medical Technologies Oy Kationiset dekstraanijohdannaiset käytettäväksi munuaisten suojaamiseen
US7345018B2 (en) 2002-04-25 2008-03-18 Reception Aps Method of treating side effects induced by therapeutic agents
WO2003080103A1 (fr) * 2002-04-25 2003-10-02 Recepticon Aps Antagonistes de megaline ou de cubiline destines a etre utilises dans la prevention de l'endommagement d'organes induit par des agents therapeutiques
WO2004084953A1 (fr) * 2003-03-24 2004-10-07 Schering Ag Modulateurs du recaptage a mediation assuree par la megaline de substances de radiotherapie et/ou radiodiagnostic dans des cellules du rein ainsi que leur utilisation en therapie et dans des diagnostics
EP1462119A1 (fr) * 2003-03-24 2004-09-29 Schering AG Modulateurs de la capture de composés radiothérapeutiques et/ou radiodiagnostiques par l'intermédiaire de la megalin des cellules rénales et leur utilisation en thérapie et diagnostique
JP2006199668A (ja) * 2005-01-24 2006-08-03 Hiroshima Univ 腎毒性抑制剤として利用できる新規ペプチドおよびこれを用いた腎毒性抑制剤、並びにこれを用いた抗菌製剤
EP1862172A1 (fr) 2006-05-31 2007-12-05 BioSynthema Inc. Combinaison d'une solution d'acides aminés et de gélatine pour l'inhibition de l'absorption rénale
US20120177571A1 (en) * 2009-07-31 2012-07-12 Riken Pancreatic endocrine cell indicating agent and utilization of same
RU2528414C1 (ru) * 2013-01-25 2014-09-20 Закрытое Акционерное Общество "Фарм-Синтез" Циклический октапептид, радиофармацевтическое средство на его основе и способ применения радиофармацевтического средства для получения лекарственных (фармацевтических) средств для лечения новообразований, экспрессирующих соматостатиновые рецепторы
WO2020224780A1 (fr) 2019-05-08 2020-11-12 ITM Isotopen Technologien München AG Acide para-aminohippurique (pah) en tant que substance protectrice rénale
US20230104323A1 (en) * 2019-12-14 2023-04-06 Manu Chaudhary Formulations of polybasic drugs to reduce multi-organ toxicity

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69026387T2 (de) * 1989-09-29 1996-11-28 Neorx Corp., Seattle, Wash. Reduktion der nichtzielspezifischen retention von immunokonjugaten und ihren metaboliten
US5843894A (en) * 1995-03-21 1998-12-01 Center For Molecular Medicine And Immunology Methods for reduced renal uptake of antibody fragments
US5728678A (en) * 1995-06-06 1998-03-17 Nestec Ltd. Method and composition for providing nutrition to a renal failure patient
CA2257353A1 (fr) * 1996-06-06 1997-12-11 Louis J. Theodore Agents de suppression de la retention hepatique

Also Published As

Publication number Publication date
DE60030722D1 (de) 2006-10-26
WO2001005383A2 (fr) 2001-01-25
EP1196154A2 (fr) 2002-04-17
DE60030722T2 (de) 2007-09-20
WO2001005383A3 (fr) 2001-07-19
JP2003504395A (ja) 2003-02-04
AU6275800A (en) 2001-02-05
EP1196154B1 (fr) 2006-09-13
FR19C1073I1 (fr) 2020-01-17
CA2379696A1 (fr) 2001-01-25
CA2379696C (fr) 2009-09-15

Similar Documents

Publication Publication Date Title
FR2808068B1 (fr) Joint d'etancheite metallique
NO20020646D0 (no) Gjenget rörforbindelse
MXPA03003463A (es) Compuestos de imidazol compensado con arilo o heteroarilo como agentes anti-inflamatorios y analgesicos.
ATE243807T1 (de) Rohrverbindung
DE60017983D1 (de) Rohrkupplung
FR2813375B1 (fr) Element filete pour joint filete tubulaire resistant au grippage
DE60011831D1 (de) Klemmring und Rohrverbindung
NO981344L (no) Rörkopling
DE60028295D1 (de) Rohrkupplung
DK1150917T3 (da) Taphane
DE69938819D1 (de) Rohrschelle
IT1313205B1 (it) Giunto con migliorata stabilita' di frenatura e minore deformazioneper eccessivo serraggio.
FR2792273B1 (fr) Desaeration d'une direction assistee
FR2797208B1 (fr) Element antivibrations pourvu d'une surete d'arrachement
NO994819D0 (no) Rörkopling
MA25834A1 (fr) Utilisation d'une combinaison de salmeterol et de propionate de fluticasone.
FR2819563B1 (fr) Visco-accouplement avec frein pour sa bague d'accouplement
NO20005314L (no) Sandbestandig fluidsvivel
KR950025392U (ko) 고강도 배수로관의 연결 접속장치
FR2793472B1 (fr) Conditionnement en deux parties emboitables l'une dans l'autre
ATE269953T1 (de) Rohrverbindung
FR2793082B1 (fr) Joint d'etancheite pour une traversee de paroi et assemblage obtenu avec ce joint
FR2806144B1 (fr) Joint d'etancheite annulaire de section quadrilobe
DE59906407D1 (de) Lösbare Rohrverbindung
FR2783543B1 (fr) Element profile pour le doublage d'une paroi realisee a l'aide d'elements nervures